Sonya Del Tredici and John Keenan
Sonya Del Tredici and John Keenan
37. Injectable Vs. Sublingual Buprenorphine
37. Injectable Vs. Sublingual Buprenorphine
37. Injectable Vs. Sublingual Buprenorphine
Monday 5th February 2024
Explore injectable vs. sublingual buprenorphine, fentanyl teratogenicity, and new genetic tests for opioid use disorder risk in this insightful episode.
47 minutes
Informative
Educational
Supportive
Engaging
Honest
About this podcast
Author:
Sonya Del Tredici and John Keenan
Overview:
Categories:
Innovative Treatments & Recovery Paths
Navigating Alcohol Dependency
Navigating Intimate Relationships
Family Recovery from Addiction
Nutritional Pathways to Recovery
Episodes:
56 (View all)
Do you want to link to this podcast?
Get the buttons here!Injectable Vs. Sublingual Buprenorphine: A Deep Dive into Addiction Treatment Options
Episode Overview
- Comparison of injectable vs. sublingual buprenorphine in terms of effectiveness and cost.
- Discussion on the teratogenicity of fentanyl.
- Insights into the FDA-approved genetic test for opioid use disorder risk.
- Exploration of patient preference and stigma in addiction treatment.
- Clinical implications for using extended-release buprenorphine.
It's a great medication, but it really does come down to patient preference.
If you're looking to stay updated on the latest in addiction medicine, this episode of Addiction Medicine Journal Club is a must-listen. Dr. Sonia del Tredici and Dr. John Keenan dive into the comparison between injectable and sublingual buprenorphine, focusing on a significant study by Marsden et al. They explore the effectiveness and cost-efficiency of monthly extended-release buprenorphine versus the daily standard of care.
This discussion is particularly valuable for those in addiction medicine practice, offering insights into patient preference, treatment retention, and stigma associated with different administration methods. But that's not all – the episode also covers groundbreaking topics like the teratogenicity of fentanyl and a new genetic test approved by the FDA to identify the risk for opioid use disorder. Dr.
Keenan sheds light on the FDA's approval process for the Avert D test, a genetic cheek swab that screens for opioid use disorder risk, and discusses its implications for clinical practice. The hosts share their thoughts on how these advancements could impact treatment decisions and patient outcomes. They also touch on the stigma surrounding methadone treatment and how extended-release buprenorphine might offer a less stigmatising alternative.
With personal anecdotes and professional insights, this episode provides a comprehensive look at the current landscape of addiction treatment. Whether you're a healthcare professional or someone interested in the latest research in addiction medicine, this episode is packed with valuable information. Tune in to understand how these findings could influence future treatment protocols and patient care.